The shot is approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. Read more at straitstimes.com. Read more at straitstimes.com.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

For a long time, scientists depended on luck to find new proteins. In 1840, for example, the Friedrich Ludwig Hünefeld, a ...

The health secretary fired all the members of the Advisory Committee on Immunization Practices late on Monday.

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.